Lantheus Holdings/ US5165441032 /
2024-03-28 8:59:56 PM | Chg. +1.79 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
62.21USD | +2.96% | 25,559 Turnover: 1.58 mill. |
-Bid Size: - | -Ask Size: - | 62.43 | 60.36 |
GlobeNewswire
03-28
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial ...
GlobeNewswire
03-04
Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Microsphere) for Pediatric Patien...
GlobeNewswire
02-13
Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Tr...
GlobeNewswire
02-08
Lantheus to Host Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast on February ...
GlobeNewswire
01-11
Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA® (Lutetium Lu 177 Dota...
GlobeNewswire
01-09
Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment,...
GlobeNewswire
01-09
Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective The...
GlobeNewswire
2023-12-18
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastat...
GlobeNewswire
2023-12-18
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastat...
GlobeNewswire
2023-10-19
Lantheus to Host Third Quarter 2023 Earnings Conference Call and Webcast on November 2, 2023, at 8:0...
GlobeNewswire
2023-09-01
Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ at the 2023 European Associati...
GlobeNewswire
2022-03-29
Lantheus Announces Collaboration to Support Prostate Cancer Clinical Development